Verastem Oncology Overview
Pro stress-test →Verastem Oncology is a biopharmaceutical company committed to developing and commercializing new medicines for RAS/MAPK pathway-driven cancers, with its pipeline focused on novel small molecule drugs including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. The company transitioned to commercial-stage status with the launch of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically approved by the FDA for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
Strategic Profile
Pro stress-test →Verastem anticipates the LGSOC commercial launch and development program will be self-sustaining by the second half of 2026. The company is focused on maximizing commercial penetration of its approved product while advancing VS-7375, a KRAS G12D inhibitor with potential best-in-class positioning across multiple solid tumor indications including pancreatic and non-small cell lung cancers.
Competitive Landscape
Pro stress-test →Verastem operates in the precision oncology space competing against larger pharma companies developing RAS/MAPK pathway inhibitors. Key competitive areas include KRAS-targeted therapies where companies like Mirati (MRTX) and Amgen have competing G12C inhibitors, and broader oncology companies. Verastem's differentiation lies in its specialized focus on KRAS G12D and combination approaches, particularly in lower-incidence tumors where it can establish category leadership.
Industry Context
Verastem Oncology operates in Biopharmaceutical / Precision Oncology.
Key facts
Founded: 2007 · Headquarters: Boston, MA, United States · Revenue: $30.9M (2025 preliminary)